New test could better predict pancreatic tumor danger
NCT ID NCT06406387
Summary
This study aims to see if checking for the loss of two specific proteins (ATRX and DAXX) in small biopsy samples taken before surgery can help doctors better predict how aggressive a pancreatic neuroendocrine tumor will be. Researchers will follow 100 patients with these non-functional tumors to see if the protein test, combined with the current grading method, gives a more accurate picture of the tumor's future behavior and the patient's prognosis. The goal is to gather knowledge that could lead to more personalized treatment plans in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Verona
Verona, Italy
Conditions
Explore the condition pages connected to this study.